Research Article

LASSO Model Better Predicted the Prognosis of DLBCL than Random Forest Model: A Retrospective Multicenter Analysis of HHLWG

Table 1

The baseline characteristics between the training cohort and the validation cohort.

VariablesTraining cohortValidation cohort

Gender (%)
 Male451 (53.2)203 (55.9)0.416
 Female397 (46.8)160 (44.1)
Age (year)62.00 (52.00, 70.00)62.00 (52.00, 70.00)0.903
TC (mmol/L)4.32 (3.68, 4.96)4.23 (3.67, 4.96)0.730
ALB (g/L)38.80 (34.80, 42.80)39.00 (34.40, 43.35)0.744
RBC (1012/L)4.10 (3.66, 4.47)4.06 (3.73, 4.50)0.565
HB (g/L)124.00 (108.00, 135.00)123.00 (108.00, 138.00)0.442
PLT (109/L)217.00 (165.00, 269.00)213.00 (154.00, 272.50)0.304
LDH (U/L)236.00 (185.00, 404.25)233.00 (181.20, 350.00)0.328
Ki-670.75 (0.60, 0.80)0.70 (0.60, 0.80)0.915
B symptom (%)
 Absence636 (75.0)264 (72.7)0.449
 Presence212 (25.0)99 (27.3)
CNS involvement (%)
 Absence761 (89.7)333 (91.7)0.332
 Presence87 (10.3)30 (8.3)
BM involvement (%)
 Absence776 (91.5)333 (91.7)0.987
 Presence72 (8.5)30 (8.3)
Liver involvement (%)
 Absence808 (95.3)343 (94.5)0.661
 Presence40 (4.7)20 (5.5)
Ann Arbor stage (%)
 I/II391 (46.1)166 (45.7)0.954
 III/IV457 (53.9)197 (54.3)
NCCN-IPI (%)
 LR/LIR477 (56.2)193 (53.2)0.355
 HIR/HR371 (43.8)170 (46.8)
IPI (%)
 LR/LIR529 (62.4)221 (60.9)0.743
 HIR/HR318 (37.5)141 (38.8)
Bulky (%)
 Absence799 (94.2)343 (94.5)0.961
 Presence49 (5.8)20 (5.5)

Note: TC: total cholesterol; ALB: albumin; RBC: red blood cell count; HB: hemoglobin; PLT: platelet; LDH: lactate dehydrogenase; CNS involvement: central nervous system involvement; BM involvement: bone marrow involvement; IPI: International Prognostic Index.